Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Therapy
Etanercept does not appear to increase morbidity or mortality rates in HIV/AIDS
August 14th, 2006
Etanercept does not appear to increase morbidity or mortality rates in HIV/AIDS. "Etanercept, a soluble p75 tumor necrosis factor receptor:FC (TNFR:FC) fusion protein for plasma cytokines, specifically tumor necrosis factor-alpha (TNF-alpha), is used in the treatment of immune-mediated rheumatic diseases. "To our knowledge, the use of etanercept in patients with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) is relatively uncommon," researchers in the United States report. According to the authors, "The main purpose of this short review is to examine the safety of etanercept in patients with...
Source: Stem Cell Week (2006-08-14)
|
